Profound Medical and Telix Partner to Expand PSMA-Informed Prostate Cancer Care
Event summary
- Profound Medical and Telix Pharmaceuticals entered a co-education agreement on October 9, 2026, to advance PSMA-informed prostate cancer care.
- The partnership aims to educate physicians on the complementary roles of Telix’s PSMA-PET imaging technologies and Profound’s MRI-guided TULSA-PRO platform.
- Profound plans to integrate PSMA-PET–MR image-fusion capabilities into its Treatment Delivery Console software for enhanced treatment planning.
- The collaboration includes participation in medical society meetings, key opinion leader programs, and the development of educational content.
The big picture
The partnership between Profound Medical and Telix Pharmaceuticals underscores the growing importance of theranostics in prostate cancer care, combining advanced molecular imaging with precision therapy. This collaboration aligns with broader industry trends toward personalized medicine and the integration of diagnostic and therapeutic technologies to improve patient outcomes. The strategic alliance aims to enhance physician education and patient selection, potentially broadening the addressable market for TULSA-PRO.
What we're watching
- Market Expansion
- How the integration of PSMA-PET imaging will affect the adoption and market reach of TULSA-PRO.
- Clinical Evidence
- Whether the collaboration will accelerate the generation of clinical evidence supporting PSMA-informed treatment pathways.
- Technological Integration
- The pace at which Profound can develop and deploy PSMA-PET–MR image-fusion capabilities in its Treatment Delivery Console.
Related topics